INT78181

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1998
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 4.46
Pain Relevance 0.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (EDNRB) signal transducer activity (EDNRB)
Anatomy Link Frequency
smooth muscle cells 1
brainstem 1
EDNRB (Homo sapiens)
Pain Link Frequency Relevance Heat
medulla 3 99.28 Very High Very High Very High
antagonist 142 99.16 Very High Very High Very High
Morphine 8 98.12 Very High Very High Very High
Kinase C 5 60.24 Quite High
metalloproteinase 16 40.64 Quite Low
agonist 1 12.80 Low Low
Bioavailability 9 7.24 Low Low
cytokine 4 6.40 Low Low
Pain 13 5.00 Very Low Very Low Very Low
headache 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Reprotox - General 1 32 99.04 Very High Very High Very High
Skin Cancer 28 98.80 Very High Very High Very High
Death 11 97.12 Very High Very High Very High
Malignant Neoplastic Disease 12 95.80 Very High Very High Very High
Cancer 130 91.12 High High
Pulmonary Hypertension 219 88.52 High High
Prostate Cancer 2 87.16 High High
Ovarian Cancer 46 83.28 Quite High
Increased Venous Pressure Under Development 21 83.20 Quite High
Disease 48 79.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Upregulation of ETA receptors and downregulation of ETB receptors in the brainstem with high doses of morphine may indicate possible effects on cerebral vascular tone.
Negative_regulation (downregulation) of ETB in brainstem associated with medulla and morphine
1) Confidence 0.57 Published 1998 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 9795754 Disease Relevance 0 Pain Relevance 0.63
ET-1 levels were elevated, consistent with a concomitant blockade of the endothelial ETB receptor.
Negative_regulation (blockade) of ETB
2) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605321 Disease Relevance 0.53 Pain Relevance 0.04
The ETA receptors are primarily expressed on vascular smooth muscle cells and cardiac myocytes; in contrast, ETB receptors are localized predominantly on endothelial cells, and to a lesser extent, on smooth muscle cells and on fibroblasts (Fig. 2) (Dupuis 2001).
Negative_regulation (localized) of ETB in smooth muscle cells
3) Confidence 0.41 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994051 Disease Relevance 0.39 Pain Relevance 0.03
A strategically important question that arises is whether selective ETA receptor antagonism should result in better clinically efficacy than blockade of both ETA and ETB (Langleben 2007).
Spec (whether) Negative_regulation (blockade) of ETB
4) Confidence 0.25 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761178 Disease Relevance 0.68 Pain Relevance 0.09
In prostate cancer, key components of the ET-1 clearance pathway, ETB and neutral endopeptidease (NEP), are diminished, resulting in an increase in local ET-1 concentrations.
Negative_regulation (diminished) of ETB and neutral endopeptidease associated with reprotox - general 1
5) Confidence 0.25 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 1.29 Pain Relevance 0.03
Thus, ETBR blockade by the ETBR peptide antagonist BQ788 resulted in growth inhibition and death of melanoma cells in vivo and in vitro [50].
Negative_regulation (blockade) of ETBR associated with antagonist, skin cancer and death
6) Confidence 0.24 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 1.57 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox